Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.
about
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
P2860
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Re-challenge with catumaxomab ...... esults from the SECIMAS study.
@en
Re-challenge with catumaxomab ...... esults from the SECIMAS study.
@nl
type
label
Re-challenge with catumaxomab ...... esults from the SECIMAS study.
@en
Re-challenge with catumaxomab ...... esults from the SECIMAS study.
@nl
prefLabel
Re-challenge with catumaxomab ...... esults from the SECIMAS study.
@en
Re-challenge with catumaxomab ...... esults from the SECIMAS study.
@nl
P2093
P2860
P1433
P1476
Re-challenge with catumaxomab ...... esults from the SECIMAS study.
@en
P2093
Armando Santoro
Frederik Marmé
Hilke Friccius-Quecke
Holger Martinius
Jalid Sehouli
Klaus Pietzner
Per Rosenberg
Radoslav Chekerov
P2860
P2888
P356
10.1007/S12032-014-0308-X
P577
2014-11-04T00:00:00Z
P6179
1007979665